TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.
Location: United States, California, Los Angeles
Total raised: $158M
Investors 1
| Date | Name | Website |
| 02.11.2025 | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.04.2024 | Series B | $158M | - |
Mentions in press and media 8
| Date | Title | Description |
| 25.11.2024 | TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline | - |
| 10.04.2024 | TORL BioTherapeutics Raises $158M in Series B-2 Financing | TORL BioTherapeutics, a Los Angeles, CA-based clinical-stage biotechnology company, raised $158M in Series B-2 funding. The round, which brought the total amount to $350M, was led by Deep Track Capital, with participation from RA Capital Ma... |
| 13.04.2023 | TORL BioTherapeutics Launches With $158M | LOS ANGELES, CA, TORL BioTherapeutics, a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B. >> Click here for more fundi... |
| 13.04.2023 | TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics | TORL BioTherapeutics LLC (TORL), a biopharmaceutical company focused on developing new biologics for cancer treatment, announced today its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug ... |
| - | TORL BioTherapeutics | “TORL Biotherapeutics” |
| - | TORL BioTherapeutics | - |
| - | TORL BioTherapeutics | “TORL BioTherapeutics, LLC” |
| - | TORL BioTherapeutics Raises $158 Million To Develop New Biologics For Cancer Treatment | TORL BioTherapeutics – a biopharmaceutical company focused on developing new biologics for cancer treatment – announced its public launch and the closing of a $158 million Series B financing. TORL’s pipeline of antibody-drug conjugates (ADC... |